National Retrospective Survey on the Prevalence of Fatty Pancreas in Patients with Pancreatic Cancer

National Retrospective Survey on the Prevalence of Fatty Pancreas in Patients with Pancreatic Cancer - Fatty Pancreas in Pancreatic Cancer: A Nationwide Retrospective Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061420

Enrollment

1000

Registered

2026-05-27

Start date

2026-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer, Pancreatic neuroendocrine tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All of the following criteria must be met: 1. Patients who underwent distal pancreatectomy for cancer of the pancreatic tail or neuroendocrine tumor of the pancreatic tail between January 2015 and December 2020, with pathologically confirmed pancreatic malignancy or pancreatic neuroendocrine tumor 2. Patients who underwent preoperative abdominal CT (both non-contrast and contrast-enhanced) 3. Patients treated at institutions designated as training hospitals by the Japan Pancreas Society

Exclusion criteria

Exclusion criteria: Any of the following: 1. Patients with acute pancreatitis or chronic pancreatitis (early chronic pancreatitis is not excluded) 2. Patients with extensive pancreatic atrophy 3. IPMN with worrisome features 4. Patients who had already undergone pancreatectomy or splenectomy prior to the pancreatic cancer diagnosis 5. Patients who received preoperative chemotherapy 6. Functional neuroendocrine tumors of the pancreas 7. Cases deemed unsuitable for fat measurement based on imaging 8. Others deemed inappropriate by the principal/sub-investigator

Design outcomes

Primary

Measure	Time frame
Prevalence (proportion) of fatty pancreas Definition: Pancreatic CT attenuation < 30 HU on non-contrast CT (suggesting>10% fat accumulation) Assessment timing: Preoperative CT images (surgical cases between January 2015 and December 2020) assessed by central review	—

Secondary

Measure	Time frame
1. Comparison of clinical backgrounds between fatty pancreas and non-fatty pancreas groups (age, sex, BMI, diabetes, smoking, alcohol, etc.) 2. Comparison of prognosis (overall survival) between the two groups 3. Comparison of postoperative pancreatic fistula (POPF) between the two groups 4. Exploration of prognostic factors for pancreatic cancer (Cox regression) 5. Exploration of risk factors for pancreatic fat accumulation (multiple regression, logistic regression, modified Poisson regression) 6. Pathological assessment of fatty pancreas (distribution pattern of pancreatic fat, presence of lipid droplets in acinar cells, etc.)	—

Measure

Time frame

1. Comparison of clinical backgrounds between fatty pancreas and non-fatty pancreas groups (age, sex, BMI, diabetes, smoking, alcohol, etc.) 2. Comparison of prognosis (overall survival) between the two groups 3. Comparison of postoperative pancreatic fistula (POPF) between the two groups 4. Exploration of prognostic factors for pancreatic cancer (Cox regression) 5. Exploration of risk factors for pancreatic fat accumulation (multiple regression, logistic regression, modified Poisson regression) 6. Pathological assessment of fatty pancreas (distribution pattern of pancreatic fat, presence of lipid droplets in acinar cells, etc.)

—

Countries

Japan

Contacts

Public ContactREIKO ASHIDA

Wakayama Medical University Second Department of Internal Medicine

fat-panc@wakayama-med.ac.jp073-447-2300

Outcome results